People of all ages can get norovirus, but more severe infections occur in children younger than five years old, older adults and people with weakened immune systems. Symptoms typically develop within ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...